Francesco De Rubertis
Director @ Critical Pressure
Geneva, Switzerland
Francesco De Rubertis is a Series A investor at Critical Pressure in Geneva focused on Biotechnology and Pharmaceutical. Francesco De Rubertis is the co-founder and Partner at Medicxi. He is the Board of Director at Ottimo Pharma. He attended the University of Geneva.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Francesco De Rubertis invests in
Stages Francesco De Rubertis invests in
Countries Francesco De Rubertis invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $1.2M–$100M
- Series A
- $11M–$140M
- Series B
- $13M–$132M
Investment Focus
Industry
- Biotechnology 9 (43%)
- Pharmaceutical 5 (24%)
- Health Care 4 (19%)
- Medical 3 (14%)
- Therapeutics 3 (14%)
Stage
- Series A 6 (29%)
- Series B 5 (24%)
- Seed 4 (19%)
- Series C 2 (10%)
- Pre-Seed 1 (5%)
Country
- United States 5 (24%)
- China 1 (5%)
- Spain 1 (5%)
- Ireland 1 (5%)
- Switzerland 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
D3 Bio
|
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $108M / Series B / Dec 09, 2025 | |
Ottimo Pharma
|
Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | $140M / Series A / Dec 19, 2024 | |
|
Ottimo Pharma
|
Ottimo Pharma is a private biotechnology company dedicated to enhancing cancer treatment outcomes and minimizing the overall healthcare burden. | Seed / Oct 28, 2024 | |
|
D3 Bio
|
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, our new medicine development approach is fundamentally differentiated. We do not just only start with science in the lab. First, we pinpoint the greatest unmet patient and market needs – whereexisting standard-of-care approaches yield unsatisfactory clinical outcomes. Then we take those insights into the lab to guide the identification of fit for purpose science and technology and define our drug development path. | $62M / Series A / Apr 08, 2024 | |
Alys Pharmaceuticals
|
Alys Pharmaceuticals engages in immuno-dermatology services. The company is reshaping the treatment landscape through advanced scientific innovations and a strong research and development-focused multi-platform pipeline. Alys emerged as a result of the strategic aggregation of 6 asset-centric companies backed by Medicxi. | $100M / Seed / Feb 12, 2024 | |
Aldena Therapeutics
|
Aldena Therapeutics is a private biotech startup that invented siRNA-based treatments for dermatological conditions. | $30M / Series A / Mar 16, 2023 | |
Velada
|
Velada is an app that helps users find the ideal restaurant for any occasion by utilizing data to provide personalized recommendations. Tjey also have a proprietary algorithm that uses data from its users' preferences and app behavior to make personalized recommendations, making Velada the first smart restaurant guide. However, without an appor resource that provides a dedicated local guide, travelers frequently find themselves in tourist traps when it comes to their culinary experience. | $1.2M / Seed / Oct 05, 2022 | |
|
Velada
|
Velada is an app that helps users find the ideal restaurant for any occasion by utilizing data to provide personalized recommendations. Tjey also have a proprietary algorithm that uses data from its users' preferences and app behavior to make personalized recommendations, making Velada the first smart restaurant guide. However, without an appor resource that provides a dedicated local guide, travelers frequently find themselves in tourist traps when it comes to their culinary experience. | $1.1M / Pre-Seed / Oct 05, 2022 | |
Rivus Pharmaceuticals
|
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity. | $132M / Series B / Sep 22, 2022 | |
|
Rivus Pharmaceuticals
|
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health. Rivus Pharmaceuticals is dedicated to improving cardio-metabolic health by developing controlled metabolic accelerators (CMAs) that address the underlying metabolic risk factors for cardiovascular mortality and morbidity. | $35M / Series A / Jul 20, 2021 | |
| See all 21 investments → | |||
Co-Investors
About Critical Pressure
Critical Pressure is a provider of drugs designed to treat to treat vascular dysfunction and shock. The company's technology has the potential to change clinical practice without the potentially harmful effects of excess fluid administration and toxicities associated with the currently available catecholamine-based vasoactive agents, providingthe possibility of supportive therapy during the critical period of haemodynamic compromise.
Critical Pressure Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bob Schroff
COO
|
|||
David Grainger
CEO
|
|||
|
Francesco De Rubertis
Director
|
|||
James M. Leiper
CSO
|
|||
Simon Lambden
CMO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Francesco De Rubertis invest in?
Francesco De Rubertis invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Francesco De Rubertis's check size?
Francesco De Rubertis typically joins rounds of $1.2M–$100M at Seed, $11M–$140M at Series A and $13M–$132M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Francesco De Rubertis participates in.
How do I contact Francesco De Rubertis?
Public channels for Francesco De Rubertis include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Francesco De Rubertis last invest?
The most recent investment recorded for Francesco De Rubertis closed in Dec 2025. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
